Hypersensitivity to plasma exchange in a patient with thrombotic thrombocytopenic purpura

Journal of Clinical Apheresis

Volumn 24, Issue 1, 2009, Pages 18-20

  Lalmuanpuii, Judy ^a   Yalamanchili, Kiran ^a   Fircanis, Sophia ^a   Nelson, John C ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Plasma exchange; Rituximab; Thrombotic thrombocytopenic purpura; Von Willebrand factor cleaving protease

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BILIRUBIN; HAPTOGLOBIN; LACTATE DEHYDROGENASE; PREDNISOLONE; RITUXIMAB; TRIACYLGLYCEROL LIPASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD SMEAR; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG RESPONSE; ENZYME ACTIVITY; FATIGUE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERSENSITIVITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LABORATORY TEST; LEUKOCYTE COUNT; PHYSICAL EXAMINATION; PLASMAPHERESIS; REMISSION; RETICULOCYTE COUNT; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ADAM PROTEINS; ANTIBODY FORMATION; AUTOANTIBODIES; FEMALE; HUMANS; HYPERSENSITIVITY; MIDDLE AGED; PLASMA EXCHANGE; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 63249131371     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20183     Document Type: Article

References (10)

1. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot G, Malot S, Heshmati F, Mira J, Boulanger E, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004;83:233-244.
2. Baron B, Martin M, Sucharetza B, Jeon H, Baron J. Four patients with both thrombotic thrombocytopenic purpura and autoimmune thrombocytopenic purpura: the concept of a mixed immune thrombocytopenia syndrome and indications for plasma exchange. J Clin Apher 2001;16:179-185.
3. Zheng X, Kaufman R, Goodnough L, Sadler J. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004;103:4043-4049.
4. Mori Y, Wada H, Gabazza E, Minami N, Nobori T, Shiku H, Yagi H, Ishizashi H, Matsumoto M, Fujimura Y. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of VWF-cleaving protease activity. Transfusion 2002;42:572-580.
5. Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot G, Daubin C, Bordessoule D, Pène F, Mira J, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2006;132:66-74.
6. Blood Center of Wisconsin. Available at: http://www.bloodcenter.com. Acessed on 6 May 2008.
7. Böhm M, Betz C, Miesbach W, Krause M, von Auer C, Geiger H, Scharrer I. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 2005;129: 644-652.
8. Studt J, Hovinga J, Radonic R, Gasparovic V, Ivanovic D, Merkler M, Wirthmueller U, Dahinden C, Furlan M, Lämmle B. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood 2004;103:4195-4197.
9. Cataland S, Jin M, Lin S, Kennedy M, Kraut E, George J, Wu H. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol 2007;139:486-493.
10. Fakhouri F, Vernant J, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grünfeld JP. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106:1932-1937.